Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 7/20 | 0.81 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.81 |
| ▸ | TLR4 | O00206 | 4/20 | 0.81 |
| ▸ | DRD2 | P14416 | 3/20 | 0.81 |
| ▸ | MAPT | P10636 | 2/20 | 0.81 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.81 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.81 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.81 |
| ▸ | MLNR | O43193 | 1/20 | 0.81 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.81 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.81 |
| ▸ | APP | P05067 | 1/20 | 0.81 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.81 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.81 |
| ▸ | HTR1A | P08908 | 1/20 | 0.81 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.81 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.81 |
| ▸ | GAA | P10253 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17946163 | 0.97 | ADRB2 (0.76) | ADRB2ADRB3TLR4DRD2MAPT | |
| SCHEMBL28985970 | 0.90 | ADRB2 (0.73) | ADRB2ADRB3TLR4DRD2MAPT | |
| Carvedilol SCHEMBL29370188 | 0.90 | ADRB2 (1.00) | ADRB2ADRB3TLR4DRD2MAPT | |
| Carvedilol SCHEMBL1560204 | 0.90 | ADRB2 (1.00) | ADRB2ADRB3TLR4DRD2MAPT | |
| (R)-Carvedilol SCHEMBL29744872 | 0.90 | ADRB2 (1.00) | ADRB2ADRB3TLR4DRD2MAPT | |
| Carvedilol SCHEMBL1172788 | 0.90 | ADRB2 (1.00) | ADRB2ADRB3TLR4DRD2MAPT | |
| (R)-Carvedilol SCHEMBL232110 | 0.90 | ADRB2 (1.00) | ADRB2ADRB3TLR4DRD2MAPT | |
| Carvedilol SCHEMBL10082334 | 0.90 | ADRB2 (1.00) | ADRB2ADRB3TLR4DRD2MAPT | |
| SCHEMBL19691083 | 0.90 | ADRB2 (0.85) | ADRB2ADRB3TLR4DRD2MAPT | |
| Carvedilol SCHEMBL29687280 | 0.90 | ADRB2 (1.00) | ADRB2ADRB3TLR4DRD2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160214973-A1 | STORE OVERLOAD-INDUCED CALCIUM RELEASE INHIBITORS AND METHODS FOR PRODUCING AND USING THE SAME | UTI LIMITED PARTNERSHIP (CA) | 2016-07-28 | — | — | US | disclosed |
| US-20160214973-A1 | STORE OVERLOAD-INDUCED CALCIUM RELEASE INHIBITORS AND METHODS FOR PRODUCING AND USING THE SAME | UTI LIMITED PARTNERSHIP (CA) | 2016-07-28 | — | — | US | disclosed |
| WO-2015031914-A1 | STORE OVERLOAD-INDUCED CALCIUM RELEASE INHIBITORS AND METHODS FOR PRODUCING AND USING THE SAME | UTI LIMITED PARTNERSHIP (CA) | 2015-03-05 | — | — | WO | disclosed |
| US-8883207-B2 | Controlled release carvedilol formulation | TSH BIOPHARM CORPORATION LTD. (TW) | 2014-11-11 | — | — | US | disclosed |
| US-8716191-B2 | Method of preparing an adduct | UNIVERSITE DE STRASBOURG (FR) | 2014-05-06 | — | — | US | disclosed |
| US-8344159-B2 | Carvedilol phosphate sesquihydrate | MYLAN LABORATORIES LIMITED (IN) | 2013-01-01 | — | — | US | disclosed |
| US-20120245212-A1 | CONTROLLED RELEASE CARVEDILOL FORMULATION | INNOPHARMAX, INC. (TW) | 2012-09-27 | — | — | US | disclosed |
| US-20120115751-A1 | METHOD OF PREPARING AN ADDUCT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-05-10 | — | — | US | disclosed |
| WO-2009116069-A2 | PROCESS FOR PREPARATION OF 1-(9H-CARBAZOL-4-YLOXY)-3-[[2-(2- METHOXYPHENOXY) ETHYL] AMINO]-2-PROPANOL | IPCA LABORATORIES LIMITED (IN) | 2009-09-24 | — | — | WO | disclosed |
| EP-1741700-B1 | Process for the preparation of carvedilol | IPCA LAB LTD (IN) | 2008-12-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245212-A1 | CONTROLLED RELEASE CARVEDILOL FORMULATION | ADRB1, ADRB2, ADRA2A | ADRB2 2/4885ADRB3 6/4885TLR4 1572/4885 |
| US-20160214973-A1 | STORE OVERLOAD-INDUCED CALCIUM RELEASE INHIBITORS AND METHODS FOR PRODUCING AND USING THE SAME | ORAI1, RYR2, CASR | ADRB2 751/4885ADRB3 1943/4885TLR4 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.